Bruker (NASDAQ:BRKR) Stock Price Target Raised at Citigroup

Bruker (NASDAQ:BRKR) had its price target increased by analysts at Citigroup from $53.00 to $64.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “neutral” rating on the medical research company’s stock. Citigroup‘s price objective indicates a potential upside of 10.33% from the company’s current price.

BRKR has been the subject of a number of other reports. JPMorgan Chase & Co. cut shares of Bruker from an “overweight” rating to a “neutral” rating and set a $60.00 price objective for the company. in a research note on Wednesday, October 14th. Zacks Research downgraded shares of Bruker from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 2nd. Guggenheim raised their target price on shares of Bruker from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Weiss Ratings reiterated a “sell (d+)” rating on shares of Bruker in a report on Monday, August 31st. Finally, TD Cowen lifted their target price on shares of Bruker from $60.00 to $62.00 and gave the stock a “hold” rating in a report on Tuesday, October 13th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $60.57.

Bruker Stock Down 9.1%

Shares of NASDAQ BRKR traded down $5.78 during mid-day trading on Thursday, reaching $58.01. 3,262,133 shares of the company traded hands, compared to its average volume of 2,383,511. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.92 and a current ratio of 1.85. The stock has a market cap of $8.84 billion, a PE ratio of -82.87, a price-to-earnings-growth ratio of 1.73 and a beta of 1.26. The company’s fifty day moving average is $58.95 and its two-hundred day moving average is $50.48. Bruker has a fifty-two week low of $32.37 and a fifty-two week high of $68.98.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Wednesday, November 4th. The medical research company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.42 by $0.14. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%. The business had revenue of $874.00 million for the quarter, compared to the consensus estimate of $865.16 million. During the same period last year, the business earned $0.45 EPS. The firm’s revenue was up 1.6% compared to the same quarter last year. On average, analysts expect that Bruker will post 2.12 earnings per share for the current year.

Insider Activity

In related news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total transaction of $105,740.00. Following the transaction, the vice president owned 134,806 shares of the company’s stock, valued at approximately $7,127,193.22. The trade was a 1.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 27.20% of the company’s stock.

Institutional Trading of Bruker

A number of hedge funds have recently bought and sold shares of BRKR. Essential Partners LLC bought a new stake in Bruker in the first quarter valued at $36,000. Global Retirement Partners LLC acquired a new position in Bruker during the second quarter worth $38,000. Provenance Wealth Advisors LLC bought a new position in shares of Bruker during the third quarter valued at $52,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Bruker by 532.9% during the first quarter. EverSource Wealth Advisors LLC now owns 1,500 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 1,263 shares during the period. Finally, Root Financial Partners LLC bought a new position in shares of Bruker during the third quarter valued at $57,000. 79.52% of the stock is owned by institutional investors.

Key Stories Impacting Bruker

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Bruker reported Q3 adjusted earnings of $0.56 per share, above the $0.42 consensus, and revenue of $874 million versus estimates of about $865 million. Revenue rose 1.6% year over year. Bruker Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Management highlighted margin expansion and strong bookings, and said U.S. academic demand returned in Q3. The company also sees potential for double-digit EPS growth in fiscal 2027, although that outlook is forward-looking. Bruker Q3 2026 Earnings Call Highlights
• Neutral Sentiment: Bruker forecast 2026 revenue of $3.52 billion to $3.56 billion, compared with a FactSet estimate of $3.56 billion. Its adjusted EPS range of $2.10 to $2.15 broadly brackets the $2.12 estimate. Bruker 2026 Revenue Outlook
• Negative Sentiment: The outlook offered little upside to expectations, while coverage also flagged a steep goodwill charge that weighed on reported results. These concerns may have overshadowed the quarterly beat and contributed to the weaker share performance. Bruker Q3 2026: Margin Surge Masks a Steep Goodwill Charge

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies.